跳至主要内容
临床试验/DRKS00007903
DRKS00007903已完成1 期

A single-center, randomized, single-blinded, controlled, pilot study to investigate the delivery of adalimumab after subcutaneous injection with a needle free injection device compared to injection with a syringe - /

IIS Innovative Injektions-Systeme GmbH & Co. KG0 个研究点目标入组 36 人开始时间: 2015年3月20日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
36

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 45 Years(—)
性别
All

入选标准

  • 1. Subjects who are able to understand and follow instructions during the study.
  • 2. Signed informed consent.
  • 3. Male or female.
  • 5. Age between 18 and 45 years (inclusive).
  • 6. In general good physical health as determined by medical and surgical history, physical examination, 12-lead electrocardiogram (ECG), vital signs, and
  • clinical laboratory tests.
  • 7. Weight within the normal range according to accepted values for the Body mass index within 18.0 to 29.4 kg/m2.
  • 8. Normal blood pressure.
  • 9. A heart rate above 50 or below 100 beats per min measured after at least 5 min rest in supine position.
  • 10. ECG recording without clinically significant
  • abnormalities.
  • There are additional details/criteria.

排除标准

  • 1. More than moderate smoker (>10 cigarettes/day).
  • 2. More than moderate alcohol consumption.
  • 3. Any history of alcohol or drug abuse.
  • 4. Use of any medication within 2 weeks before first dosing.
  • 5. Blood donation within 30 days before signing
  • informed consent to this trial.
  • 6. Demonstrating any active physical disease, acute or chronic.
  • 7. Any history of drug hypersensitivity, asthma,
  • urticaria or other severe allergic diathesis as well as current hay fever.
  • 8. Any history of chronic or recurrent metabolic, renal, hepatic, pulmonary, gastrointestinal, neurological, endocrinological, immunological, psychiatric or cardiovascular disease, myopathies, and bleeding tendency.
  • 9. Laboratory values outside the reference range that are of clinical relevance.
  • 10. Positive test for human immunodeficiency virus (HIV) antibodies or antigen.
  • 11. Positive Hepatitis B-virus surface antigen (HBsAg) test.
  • 12. Positive Anti-hepatitis C-virus antibodies (Anti-
  • 13. Pregnant or nursing women.
  • 14. Women of childbearing potential not using a highlyeffective method of birth control.
  • There are additional details/criteria.

研究者

发起方
IIS Innovative Injektions-Systeme GmbH & Co. KG

相似试验